BURLINGTON, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. Eastern Time at the Westin Grand Central Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable, non-opioid drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead product candidate, Zilretta™, has been designed to provide improved analgesic therapy for the five million patients who receive intra-articular (IA) injections for osteoarthritis (OA) of the knee annually. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an IA, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.